Literature DB >> 19829311

Vasopressin in chronic kidney disease: an elephant in the room?

Vicente E Torres1.   

Abstract

Perico et al. report that a dual arginine vasopressin (AVP) V(2) and V(1a) receptor antagonist lowers blood pressure, proteinuria, and glomerulosclerosis in 5/6 nephrectomized rats, pointing to its potential value in the treatment of chronic kidney disease (CKD). AVP likely contributes to CKD progression by its effects on renal hemodynamics, blood pressure, and mesangial and/or epithelial cells, but the relative contributions of V(2) and V(1a) receptors and potential usefulness of V(2) and V(1a) receptor antagonists remain ill defined.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19829311      PMCID： PMC2925670          DOI： 10.1038/ki.2009.325

Source DB:  PubMed          Journal:  Kidney Int        ISSN： 0085-2538            Impact factor:   10.612


  38 in total

1.  Level of hydration and renal function in healthy humans.

Authors:  P Anastasio; M Cirillo; L Spitali; A Frangiosa; R M Pollastro; N G De Santo
Journal:  Kidney Int       Date:  2001-08       Impact factor: 10.612

Review 2.  Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects.

Authors:  L Bankir
Journal:  Cardiovasc Res       Date:  2001-08-15       Impact factor: 10.787

3.  Axial heterogeneity of vasopressin-receptor subtypes along the human and mouse collecting duct.

Authors:  Monica Carmosino; Heddwen L Brooks; Qi Cai; Linda S Davis; Susan Opalenik; Chuanming Hao; Matthew D Breyer
Journal:  Am J Physiol Renal Physiol       Date:  2006-07-11

Review 4.  Sex difference in urine concentration across differing ages, sodium intake, and level of kidney disease.

Authors:  Julie Perucca; Nadine Bouby; Pierre Valeix; Lise Bankir
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2006-09-21       Impact factor: 3.619

Review 5.  Control of the renal medullary circulation by vasopressin V1 and V2 receptors in the rat.

Authors:  A W Cowley
Journal:  Exp Physiol       Date:  2000-03       Impact factor: 2.969

Review 6.  Urea and urine concentrating ability: new insights from studies in mice.

Authors:  Baoxue Yang; Lise Bankir
Journal:  Am J Physiol Renal Physiol       Date:  2005-05

7.  Effect of YM218, a nonpeptide vasopressin V(1A) receptor-selective antagonist, on rat mesangial cell hyperplasia and hypertrophy.

Authors:  Atsuo Tahara; Junko Tsukada; Yuichi Tomura; Takeshi Suzuki; Takeyuki Yatsu; Masayuki Shibasaki
Journal:  Vascul Pharmacol       Date:  2007-03-01       Impact factor: 5.773

8.  Vasopressin V2 receptor expression along rat, mouse, and human renal epithelia with focus on TAL.

Authors:  K Mutig; A Paliege; T Kahl; T Jöns; W Müller-Esterl; S Bachmann
Journal:  Am J Physiol Renal Physiol       Date:  2007-07-11

9.  Ethnic differences in urine concentration: possible relationship to blood pressure.

Authors:  Lise Bankir; Julie Perucca; Myron H Weinberger
Journal:  Clin J Am Soc Nephrol       Date:  2007-01-10       Impact factor: 8.237

10.  Vasopressin-induced nitric oxide production in rat inner medullary collecting duct is dependent on V2 receptor activation of the phosphoinositide pathway.

Authors:  Paul M O'Connor; Allen W Cowley
Journal:  Am J Physiol Renal Physiol       Date:  2007-05-16
View more
  17 in total

1.  Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.

Authors:  Vicente E Torres; Eiji Higashihara; Olivier Devuyst; Arlene B Chapman; Ronald T Gansevoort; Jared J Grantham; Ronald D Perrone; John Ouyang; Jaime D Blais; Frank S Czerwiec
Journal:  Clin J Am Soc Nephrol       Date:  2016-02-23       Impact factor: 8.237

Review 2.  Early diabetic nephropathy in type 1 diabetes: new insights.

Authors:  Petter Bjornstad; David Cherney; David M Maahs
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2014-08       Impact factor: 3.243

Review 3.  ADPKD current management and ongoing trials.

Authors:  Francesca Testa; Riccardo Magistroni
Journal:  J Nephrol       Date:  2019-12-18       Impact factor: 3.902

4.  Diabetes Complications in Childhood Diabetes-New Biomarkers and Technologies.

Authors:  Petter Bjornstad; David M Maahs
Journal:  Curr Pediatr Rep       Date:  2015-04-04

5.  Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.

Authors:  Eiji Higashihara; Vicente E Torres; Arlene B Chapman; Jared J Grantham; Kyongtae Bae; Terry J Watnick; Shigeo Horie; Kikuo Nutahara; John Ouyang; Holly B Krasa; Frank S Czerwiec
Journal:  Clin J Am Soc Nephrol       Date:  2011-09-08       Impact factor: 8.237

6.  Peripheral Insulin Resistance Is Associated with Copeptin in Patients with Chronic Kidney Disease.

Authors:  Juan Pablo Arroyo; Elvis A Akwo; Andrew S Terker; Aseel Alsouqi; Gautam Bhave; Raymond C Harris; Adriana M Hung; T Alp Ikizler
Journal:  Kidney360       Date:  2021-07-08

7.  Chronic Lithium Therapy and Urine-Concentrating Ability in Individuals With Bipolar Disorder: Association Between Daily Dose and Resistance to Vasopressin and Polyuria.

Authors:  Nahid Tabibzadeh; Emmanuelle Vidal-Petiot; Lynda Cheddani; Jean-Philippe Haymann; Guillaume Lefevre; Bruno Etain; Frank Bellivier; Emeline Marlinge; Marine Delavest; François Vrtovsnik; Martin Flamant
Journal:  Kidney Int Rep       Date:  2022-04-15

Review 8.  Experimental therapies and ongoing clinical trials to slow down progression of ADPKD.

Authors:  Maria V Irazabal; Vicente E Torres
Journal:  Curr Hypertens Rev       Date:  2013-02

9.  Validation of Surrogates of Urine Osmolality in Population Studies.

Authors:  Sonia Youhanna; Lise Bankir; Paul Jungers; David Porteous; Ozren Polasek; Murielle Bochud; Caroline Hayward; Olivier Devuyst
Journal:  Am J Nephrol       Date:  2017-06-07       Impact factor: 3.754

10.  Increased insensible water loss contributes to aging related dehydration.

Authors:  Natalia I Dmitrieva; Maurice B Burg
Journal:  PLoS One       Date:  2011-05-31       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.